[1] Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60:277-300. 10.3322/caac.20073
[2] Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4:1221–1227.
[3] Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33. doi: 10.4065/78.1.21
[4] Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010;116:5501–5506.
[5] Firth J: Haematology: multiple myeloma . Clin Med. 2019, 19:58-60. 10.7861/clinmedicine.19-1-58
[6] Anderson KC: Multiple myeloma: a clinical overview . Oncology (Williston Park). 2011, 15:3-9.
[7] Eslick R, Talaulikar D: Multiple myeloma: from diagnosis to treatment . Aust Fam Physician. 2013, 42:684-8.
[8] Korbet SM, Schwartz MM. Multiple myeloma. J Am Soc Nephrol 2006; 17: 2533–2545
[9] Nasr SH, Valeri AM, Sethi S et al. Clinicopathologic correlations in multiple myeloma: A case series of 190 patients with kidney biopsies. Am J Kidney Dis 2012; 59: 786–794
[10] Courant M, Orazio S, Monnereau A, Preterre J, Combe C, Rigothier C (2019) Incidence , prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma : a population-based registry. Nephrol Dial Transplant 1–9
[11] Hutchison CA, Cockwell P, Moroz V, Bradwell AR, Fifer L, Gillmore JD, et al. High cutoff versus high-flflux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (Eulite): A phase 2 randomised controlled trial. Lancet Haematol (2019) 6(4):e217–e28. doi: 10.1016/s2352-3026 (19)30014-6
[12] Bridoux F, Carron PL, Pegourie B, Alamartine E, Augeul-Meunier K, Karras A, et al. Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: A randomized clinical trial. Jama (2017) 318(21):2099–110. doi: 10.1001/ jama.2017.17924
[13] Hutchison CA, Batuman V, Behrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol. 2011;8:43–51.
[14] Li M, Balamuthusamy S, Simon EE, et al. Silencing megalin and cubilin genes inhibits myeloma light chain endocytosis and ameliorates toxicity in human renal proximal tubule epithelial cells. Am J Physiol Renal Physiol. 2008;295:F82–F90.
[15] Sanders PW. Mechanisms of light chain injury along the tubular nephron. J Am Soc Nephrol. 2012;23:1777–1781.
[16] Christensen EI, Birn H, Storm T, et al. Endocytic receptors in the renal proximal tubule. Physiology (Bethesda). 2012;27:223–236.
[17] Sanders PW, Herrera GA, Galla JH. Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo. Kidney Int. 1987;32:851–861.
[18] Huang ZQ, Sanders PW. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Invest. 1997;99:732–736.
[19] Ying WZ, Sanders PW. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol. 2001;58:1859–1866.
[20] Ecotière L, Thierry A, Debiais-Delpech C, et al. Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients. Nephrol Dial Transplant. 2016;31:64–72.
[21] Royal V, Leung N, Troyanov S, et al. Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. Blood. 2020;135:1833–1846.
[22] Sengul S, Zwizinski C, Batuman V. Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am J Physiol Renal Physiol. 2003;284:F1245–F1254.
[23] Wang PX, Sanders PW. Immunoglobulin light chains generate hydrogen peroxide. J Am Soc Nephrol. 2007;18:1239–1245.
[24] Basnayake K, Ying WZ, Wang PX, Sanders PW. Immunoglobulin light chains activate tubular epithelial cells through redox signaling. J Am Soc
Nephrol. 2010;21:1165–1173.
[25] Ying WZ, Wang PX, Aaron KJ, et al. Immunoglobulin light chains activate nuclear factor-kB in renal epithelial cells through a Srcdependent mechanism. Blood. 2011;117:1301–1307.
[26] Ying WZ, Wang PX, Sanders PW. Pivotal role of apoptosis signalregulating kinase 1 in monoclonal free light chain-mediated apoptosis. Am J Pathol. 2012;180:41–47.
[27] Ying WZ, Li X, Rangarajan S, et al. Immunoglobulin light chains generate proinflflammatory and profifibrotic kidney injury. J Clin Invest. 2019;129:2792–2806.
[28] Mulay SR, Anders HJ. Crystal nephropathies: mechanisms of crystalinduced kidney injury. Nat Rev Nephrol. 2017;13:226–240.
[29] Stompór T, Zab?ocki M, Pankrac K: Renal involvement in multiple myeloma . Pol Arch Med Wewn. 2012, 122:443-8.
[30] Basnayake K, Cheung CK, Sheaff M, et al.: Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney. J Clin Pathol. 2010, 63:884-7. 10.1136/jcp.2010.079236
[31] Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal signifificance: when MGUS is no longer undetermined or insignifificant. Blood. 2012;120:4292–4295
[32] Bridoux F, Leung N, Hutchison CA, et al. Diagnosis of monoclonal gammopathy of renal signifificance. Kidney Int. 2015;87:698–711.
[33] Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal signifificance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15:45–59.
[34] Yadav P, Sathick IJ, Leung N, et al. Serum free light chain level at diagnosis in myeloma cast nephropathy—a multicentre study. Blood Cancer J. 2020;10:28
[35] Uttervall K, Andreasson J, Liwing J, N?sman P, Aschan J, Nahi H (2012) Is renal impairment still a poor prognostic marker in myeloma care? A population based study including 1542 patients. Am Soc Hematol 120:5033
[36] Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA et al (2011) Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 22(6):1129–1136
[37] Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC et al (2008) Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 73(11):1282–1288
[38] Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P et al (2014) Signifcant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 25(1):195–200
[39] Cockwell P, Hutchison CA (2010) Management options for cast nephropathy in multiple myeloma. Curr Opin Nephrol Hypertens [Internet].19(6). Available from: https://journals.lww.com/co-nephrolhypertens/Fulltext/2010/11000/Management_optio
ns_for_cast_nephropathy_in.7.aspx
[40] Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, Hattersley J, Evans ND, Chappell MJ, Cook M, Goehl H, Storr M, Bradwell AR: Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007;18:886–895.
[41] Sanders PW: Pathogenesis and treatment of myeloma kidney. J Lab Clin Med 1994;124:484–488.
[42] Hutchison CA, Bladé J, Cockwell P, Cook M, Drayson M, Fermand JP, Kastritis E, Kyle R, Leung N, Pasquali S, Winearls C, International Kidney and Monoclonal Gammopathy Research Group: Novel approaches for reducing free light chains in patients with myeloma kidney. Nat Rev Nephrol 2012;8:234–243.
[43] Walther C, Podoll AS, Finkel KW: Treatment of acute kidney injury with cast nephropathy. Clin Nephrol 2014;82:1-6.
[44] Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S, Hattersley J, Evans ND, Chappel MJ, Sampson P, Foggensteiner L, Adu D, Cockwell P: Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009;4:745- 754.
[45] Hutchison CA, Harding S, Mead G, Goehl H, Storr M, Bradwell A, et al.
Serum free-light chain removal by high cutoff hemodialysis: Optimizing removal
and supportive care. Artif Organs (2008) 32(12):910–7. doi: 10.1111/j.1525-
1594.2008.00653.x
[46] Dimopoulos MA, Kastritis E, Rosinol L, Bladé J，Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia (2008) 22(8):1485– 93. doi: 10.1038/leu.2008.131
[47] Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G, et al.
Safety and effificacy of bortezomib-based regimens for multiple myeloma patients
with renal impairment: a retrospective study of Italian myeloma network
GIMEMA. Eur J Haematol (2010) 84(3):223–8. doi: 10.1111/j.1600- 0609.2009.01385.x
[48] San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D,
Stadtmauer EA, et al. Effificacy and safety of bortezomib in patients with renal
impairment: results from the APEX phase 3 study. Leukemia (2008) 22(4):842–9.
doi: 10.1038/sj.leu.2405087
[49]Gerth HU, Pohlen M, G?rlich D, et al. Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study.?PLoS One. 2016;11(5):e0154993. Published 2016 May 6. doi:10.1371/journal.pone.0154993
[50] Heyne N, Denecke B, Guthoff M, et al. Extracorporeal light chain elimination: high cut-off (HCO) haemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury. Ann Hematol. 2012;91:729–735.
[51] Hutchison CA, Heyne N, Airia P, et al. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant. 2012;27:3823–3828.
[52] Zannetti BA, Zamagni E, Santostefano M, et al. Bortezomib-based therapy combined with high cut-off haemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment. Am J Hematol. 2015;90:647–652.
[53] Curti A, Schwarz A, Trachsler J, et al. Therapeutic effificacy and cost effectiveness of high cut-off dialyzers compared to conventional dialysis in patients with cast nephropathy. PLoS One. 2016;11:e0159942.
[54] Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109:2604–2606.
[55] Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identifification of predictive factors. Clin Lymphoma Myeloma. 2009;9:302–306.
[56] Morabito F, Gentile M, Ciolli S, et al. Safety and effificacy of bortezomib
based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol. 2010;84:223–228.
[57] Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol. 2010;28: 4635–4641.
[58]Tarragón B, Ye N, Gallagher M, Sen S, Portolés JM, Wang AY. Effect of high cut-off dialysis for acute kidney injury secondary to cast nephropathy in patients with multiple myeloma: a systematic review and meta-analysis.?Clin Kidney J. 2020;14(8):1894-1900. Published 2020 Dec 12. doi:10.1093/ckj/sfaa22
[59] Dimopoulos MA, Sonneveld P, Leung N et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment.
J Clin Oncol 2016; 34: 1544–1557
[60] Berni Wennekers A, Martin Azara MP, Dourdil Sahun V, Bergasa Liberal B, ? Ruiz Laiglesia JE, Vernet Perna P, et al. Thirteen treated of acute renal failure secondary to multiple myeloma with high cut off fifilters. Nefrologia (2016) 36
(4):418–26. doi: 10.1016/j.nefro.2016.03.011
[61]Grima DT, Hutchison CA. Modelled cost-effectiveness of high cutoff haemodialysis compared to standard haemodialysis in the management of myeloma kidney. Curr Med Res Opin 2011;27(2):383-91
[62]Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet (2019) 394(10192):29–38. doi: 10.1016/S0140-6736(19)31240-1
[63]Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med (2016) 375(8):754–66. doi: 10.1056/NEJMoa1606038
